Hypolipidemic effect of sitagliptin, voglibose and glimepiride in combination with metformin in patients with type 2 diabetes mellitus at a tertiary care teaching hospital: a comparative study
Keywords:Diabetic dyslipidemia, Glimepiride, Metformin, Sitagliptin, Voglibose
Background: The prevalence of coronary artery disease has been increased in diabetic dyslipidemia; hence the present study would like to compare the dyslipidemic effects of Sitagliptin, Voglibose, and Glimepiride in combination with Metformin in type 2 diabetes mellitus patients.
Methods: This study was a Prospective, Randomized Clinical trial conducted at SRM medical College Hospital and Research centre. Potheri, Kancheepuram District in diabetic outpatient department after obtaining approval from Institutional Ethics Committee. The patients receiving antidiabetic drugs were divided into three groups. Patients received Metformin with Sitagliptin were grouped as I, Metformin with Voglibose were named as Group II and Metformin with Glimepiride were marked as Group III. Based on the inclusion and exclusion criteria, in each group, 40 patients were assigned as per simple randomization method. The level of lipid profile and BMI was evaluated at the end of 6 months.
Results: There was a significant reduction of Total Cholesterol (TC) in Group II and Group III (p value- <0.001, <0.006). Group I showed significant elevation of HDL-C level with the p value of <0.03. Group III showed significant reduction of Triglyceride (TG) level with the p value of <0.04, significant reduction of Low Density Lipoprotein Cholesterol (LDL-C) level with the p value of <0.02 and significant reduction in Very Low Density Lipoprotein Cholesterol (VLDL-C) level with the p value of <0.05. There was no significant reduction in Body Mass Index (BMI) among the groups. On multiple comparisons, Group III showed higher efficacy in reducing TC, TG, LDL-C and VLDL-C levels.
Conclusions: The results of this study were analysed and it could be concluded as Metformin with Glimepiride combination (Group III) showed significant reduction of TC, TG, LDL-C and VLDL-C levels.
Unwin N, Whiting D, Gan D, Jacqmain O, Ghyoot G. International Diabetic Federation. IDF Diabetes Atlas. 4th Ed. 2009:12.
Thankappan KR, Shah B, Mathur P, Sarma PS, Srinivas G, Mini GK, et al. Risk factor profile for chronic non-communicable diseases- Results of a community based study in Kerala, India. Indian J Med Res. 2010;131:53-63.
Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363(15):1410-8.
Management of dyslipidemia in adults with diabetes. American Diabetes Association. Diabetes Care. 2003 Jan;26(suppl 1):s83-s86.
Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, Pugh K, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003 Feb;52(2):453-62.
Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest. 1993;92(1):141-6.
Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Circulation. 1997 Jan 7;95(1):69-75.
Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation. 2002 Oct 8;106(15):1930-7.
Mooradian AD, Haas MJ, Wehmeier KR, Wong NC. Obesity-related changes in high-density lipoprotein metabolism. Obesity (Silver Spring). 2008 Jun;16(6):1152-60.
Kannel WB. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J. 1985 Nov;110(5):1100-7.
Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999 Aug 5;341(6):410-8.
Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005 Nov 26;366(9500):1849-61.
Takami K, Takeda N, Nakashima K, Takami R, Hayashi M, Ozeki S, et al. Effects of Dietary Treatment alone or Diet with Voglibose or Glyburide on abdominal adipose tissue and metabolic abnormalities in patients with newly diagnosed Type 2 Diabetes. Diabetes Care .2002 April;25(4):658-62.
Ingle PV, Talele DG. Comparative effects of metformin in combination with glimepiride and glibenclamide on lipid profile in indian patients with type 2 diabetes mellitus. Age (year, Mean, SD). Int J Pharm Pharmaceut Sci. 2011;3(Suppl 5):472-4.
Najim HD, Majeed IA, Rahmah AM. Effects of Metformin, Glimepiride and their Combination on Glycemia and Lipid Profile of NIDDM Patients-A study in Iraqis. Int J Adv Pharm Biol Chem. 2013 Apr-Jun; 2(2):2277-4688.
Monami M, Vitale V, Ambrosio ML, Bartoli N, Toffanello G, Ragghianti B, et al. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials. Adv Ther. 2012 Sep;29(9):736-46.
Shigematsu E, Yamakawa T, Kadonosono K, Terauchi Y. Effect of sitagliptin on lipid profile in patients with type 2 diabetes mellitus. J Clin Med Res. 2014;6(5):327-35.
Shinozaki K, Suzuki M, Ikebuchi M, Hirose J, Hara Y, Harano Y. Improvement of Insulin Sensitivity and Dyslipidemia with a New α-Glucosidase Inhibitor, Voglibose, in Nondiabetic Hyperinsulinemic Subjects. Metabolism. 1996 June;45(6):731-7.
Matsumoto K, Yano M, Miyake S, Ueki Y, Yamaguchi Y, Akazawa S, et al. Effects of Voglibose on Glycemic Excursions, Insulin Secretion, and Insulin Sensitivity in Non- lnsulintreated NIDDM Patients. Diabetes Care. 1998 February 24;21(2):256-60.
Jung SH, Kim DJ, Lee KW, Kim BT, Kim SS, Kim ES, et al. Effects of Voglibose and Glimepiride on body weight in patients with Type 2 Diabetes. Korean J Obes. 2005 June;14(2):94-100.
Negishi M, Shimomura K, Proks P, Shimomura Y, Mori M. Alpha glucosidase inhibitor voglibose can prevent pioglitazone-induced body weight gain in Type 2 diabetic patients. Br J Clin Pharmacol. 2008 Aug; 66(2):318-9.